Home / Success Plan (Lead-based) – Terms & Conditions
By subscribing to the Success Plan (Lead-based), you agree to the following plan-specific terms. These apply in addition to the MAI CDMO Legal Terms.
With the Success Plan (Lead-based) you get:
Note: Access to projects facilitates outreach but does not guarantee any response, lead volume, or awarded projects.
The fee is €200 per qualified lead.
Leads that do not meet the definition of a qualified lead will not be invoiced.
Payment must be made by bank transfer. Each qualified lead will be invoiced individually, and payment is due within 30 days of invoice date, to the account provided on the invoice.
A lead will be considered qualified if it comes from a specific individual, with a real and described job title, using the corporate email address of their company, representing a potential pharmaceutical client, and if the inquiry described is compatible with your capabilities (even if further discussions later prove otherwise).
In the event of non-payment, access to leads may be suspended until the payment is received in the provider’s account. During this period, the subscription will remain on the Basic Plan with reduced features.
This clause is established pursuant to the freedom of contract recognized in the Spanish Commercial Code (arts. 1 et seq.) and Civil Code (art. 1,261), as well as Law 7/1998, of April 13, on General Conditions of Contracting, last updated 16/03/2019, ensuring clarity, precision, and transparency for the parties.
2026-03-04
How strategic CDMO partnerships enable faster execution, scalable development, and smarter decision-making in modern drug innovation
See more
2026-02-23
The Backbone of Patient Safety: Navigating Aseptic Process Simulation and Equipment Qualification in Sterile Manufacturing.
See more
2026-02-17
From Random to Controlled: Navigating the Technical Evolution and Manufacturing Hurdles of Antibody-Drug Conjugates.
See more
Sterile manufacturing solutions (small molecules) in flexible bags and vials.
Activity: FDF / DRUG PRODUCTS manufacturing
Uses: Investigational, Commercial (Phase IV), Human,...
Services: Regulatory services, Development services,...
Batch Size / Reactor: Small, Medium, Large
Compliance: ISO, EMA (EU GMP), FDA (cGMP), Health Canada...
Markets: FDA (USA), EMA (EU), PMDA (Japan), Health Canada...
Fully integrated CDMO solutions for Blow-Fill-Seal (BFS), sterile multidose, non-sterile multi-dose, sachets, capsules and tablets.
Activity: FDF / DRUG PRODUCTS, PARTICLE ENGINEERING manufacturing
Uses: Commercial (Phase IV), Human
Services: Regulatory services, Development services,...
Batch Size / Reactor: Small, Medium, Large
Compliance: ISO, EMA (EU GMP), FDA (cGMP)
Markets: FDA (USA), EMA (EU)
Accueil Sites Osny. Acquired in 2011, the Osny site specializes in the development and production of highly active solid pharmaceutical forms (hormonal and allergens). This 4,000 m2 pharmaceutical plant located 36 km northwest of Paris employs around a hundred people.
Activity: FDF / DRUG PRODUCTS manufacturing
Uses: Investigational, Commercial (Phase IV), Human
Services: Regulatory services, Development services,...
Batch Size / Reactor: Small, Medium
Compliance: EMA (EU GMP), FDA (cGMP), ANVISA (Brazil B-GMP),...
Markets: FDA (USA), EMA (EU), PMDA (Japan), MHRA (UK), NMPA...
Ophtalmic and Otic - Solutions, suspensions, emulsions, ointments and gels - FDA Approved facility
Activity: FDF / DRUG PRODUCTS manufacturing
Uses: Investigational, Commercial (Phase IV), Human,...
Services: Regulatory services, Development services,...
Batch Size / Reactor: Small, Medium, Large
Compliance: ISO, EMA (EU GMP), FDA (cGMP), World Health...
Markets: FDA (USA), EMA (EU)
Cell Therapy company with excess Cleanroom capacity
Activity: FDF / DRUG PRODUCTS, BIOLOGICS, SERVICES manufacturing
Uses: Investigational, Commercial (Phase IV), Human
Services: Regulatory services, Development services,...
Batch Size / Reactor: Small, Medium
Compliance: EMA (EU GMP)
Markets: EMA (EU)
Tubilux Pharma: registered office; manufacturing facility
Activity: FDF / DRUG PRODUCTS, SERVICES manufacturing
Uses: Commercial (Phase IV), Human, Veterinary
Services: N/A
Batch Size / Reactor: Medium, Large
Compliance: EMA (EU GMP), FDA (cGMP), TGA (Australia GMP),...
Markets: FDA (USA), EMA (EU), TGA (Australia), ANVISA...
Seda Pharmaceutical Development Services specialises in integrated Pharmaceutical Development and Clinical Pharmacology.
Activity: FDF / DRUG PRODUCTS manufacturing
Uses: Investigational, Human
Services: Regulatory services, Development services,...
Batch Size / Reactor: Small, Medium
Compliance: ECOVADIS, MHRA (UK GMP)
Markets: DIGEMID (Peru), COFEPRIS (Mexico), INVIMA...
Adare Pharma is a global CDMO with sites in US and EU providing turnkey product development through commercial manufacturing expertise focused on oral dosage forms for the Pharmaceutical, Animal Health and OTC markets. Adare s proprietary technology platforms specialize in ODT s, taste masking and customized drug release.
Activity: FDF / DRUG PRODUCTS, SERVICES manufacturing
Uses: Human, Veterinary
Services: Regulatory services, Development services,...
Batch Size / Reactor: Small, Medium, Large
Compliance: ISO, EMA (EU GMP), FDA (cGMP), Health Canada...
Markets: DIGEMID (Peru), COFEPRIS (Mexico), INVIMA...
If you have any questions or suggestions, click here. We will be happy to assist you.
